In plain English
Compounded mass-market claims are a liability
If your landing page or Meta creative still sells “compounded semaglutide/tirzepatide” like a commodity, you are advertising into a risk surface platforms and regulators have already tightened.
Branded product + documented oversight
Marketing should reflect licensed distribution pathways and real prescriber supervision — not telehealth theater copy that implies every patient gets the same outcome.
No equivalence theater
Copy that frames compounded product as “just like” Wegovy/Zepbound, or that leans on before/after miracle framing, is how accounts get rejected and clinics get letters.
Your page has to survive the same review as the ad
Creative that clears Meta still dies if the landing page contradicts policy. We build both as one compliant system.
This page is marketing guidance, not legal advice. Treatment claims and clinical language should be approved by your licensed providers before publishing.
Free Compliance Teardown
Send us your live ad + landing page. We’ll mark the rejection risks and the three fixes we’d make first — whether or not you hire us.
Request a Compliance Teardown